|22nd September 2020||Advisors Llc Perceptive||1,644,785||Conversion of derivative||$0.00|
|22nd September 2020||Advisors Llc Perceptive||1,058,824||Open or private purchase||$17.00||$18,000,008.00|
|15th September 2020||Advisors Llc Perceptive||2,911,764||Open or private purchase||$4.25||$12,374,997.00|
|14th September 2020||Advisors Llc Perceptive||1,800,000||Open or private purchase||$11.00||$19,800,000.00|
|14th September 2020||Advisors Llc Perceptive||400,000||Open or private purchase||$40.00||$16,000,000.00|
|11th September 2020||Martha J Demski||2,200||Open or private purchase||$2.29||$5,038.00|
|10th September 2020||Advisors Llc Perceptive||200,000||Open or private purchase||$11.24||$2,248,000.00|
|10th September 2020||Jerrold B Grossman||5,000||Open or private purchase||$2.22||$11,100.00|
|8th September 2020||Adam S Grossman||4,000||Open or private purchase||$2.24||$8,959.60|
|8th September 2020||James Mond||4,000||Open or private purchase||$2.20||$8,800.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 0/10.
ADMA Biologics, Inc. operates as a biopharmaceutical company. It develops, manufactures, and intends to commercialize in human plasma and plasma-derived therapeutics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center and Corporate.